The company said net sales for Q3 2025 were $2.001 billion, up 9.7% on a reported basis, 8.6% on a constant currency basis and 5.0% on an organic constant currency basis.

1. 01

   The company said net sales for Q3 2025 were $2.001 billion, up 9.7% on a reported basis, 8.6% on a constant currency basis and 5.0% on an organic constant currency basis.

2. 02

   Zimmer Biomet said net earnings for Q3 were $230.9 million and diluted earnings per share were $1.16, while adjusted net earnings were $377.0 million and adjusted diluted earnings per share were $1.90, an increase of 9.2%.

3. 03

   The company said it maintained its full-year 2025 reported revenue growth guidance of 6.7% to 7.7% and adjusted diluted EPS guidance of $8.10 to $8.30, and narrowed its constant currency revenue growth guidance to 6.2% to 6.7% and its organic constant currency revenue growth guidance to 3.5% to 4.0%.

4. 04

   Zimmer Biomet said net cash provided by operating activities was $1,179.7 million for the 9 months ended September 30, 2025, and that proceeds from senior notes were $2,492.1 million and redemptions of senior notes were $863.0 million over the same period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.